Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionBispecific mAb targeting somatostatin receptor 2 (SSTR2) and CD3
Molecular Target Somatostatin receptor 2 (SSTR2) ; CD3
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat neuroendocrine tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today